Expert regulatory guidance for a faster path to drug product approval.

We support pharmaceutical and biotech innovators seeking product approvals in major global markets.


Guided by former
CMC regulators.

Learn More


From study design to
report writing & review.

Learn More


To streamline the
path to approval.

Learn More


Lifecycle strategies for
marketed products.

Learn More

What products are you looking to bring to market?

We deliver deep real-world global regulatory affairs expertise and hands-on support for:

2020 AAPS PharmSci 360

October 26 – November 3
Explore virtual sessions & schedule a 1-on-1 with the DataRevive team.

Register Now

A full-service partner for the entire product development lifecycle.

Michele Dougherty


Michele Dougherty, Ph.D.

  • Formerly FDA CDER OBP Review Chief
  • 17+ years of experience

Julia Carrier

Vice President Nonclinical

Julia Carrier, Ph.D.

  • Formerly of Pfizer
  • 18+ years in nonclinical PD, PK, and toxicology

Yong Wang

Vice President CMC Small Molecule

Yong Wang, Ph.D.

  • Formerly of FDA CDER
  • 17+ years of experience

Wayne Hutman

V.P of Clinical

H. Wayne Hutman, M.D.

  • 20+ years in pharma industry
  • Has conducted 100+ clinical trials

Image001 Revised

Vice President, Project Management

Shagun Popli

  • Formerly of Astellas, Intuitive Surgical, Genentech and J&J
  • 30 years of experience in pharmaceutical/biotech and medical device industry
Kathleen Retterson

Vice President CMC Biologics

Kathleen Retterson

  • Formerly of Spectrum, Charles River, Genzyme & Amgen
  • 30 years of experience in CMC/GMP

Make our specialists an extension of your team.

No other consulting firm maintains the depth and breadth of expertise that DataRevive has in-house. Tap it today!

Start Here

5 Gmp Inspections
Did You Know?

In one year, DataRevive completed 5 GMP pre-approval inspections for small molecule & biological products in Japan, China, Scandinavia, and the US.

View Case Studies

May 1, 2020

Resuming Business Operations Following the COVID-19 Pandemic: Part Two

Read Blog Post

May 7, 2020

Avoiding and Reacting To Human Tissue, Cell And Gene Therapy Enforcement Actions: Communication Is Key

Read Blog Post